Tag: Kodiak Sciences

Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial

pallavi123- February 27, 2022

Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase 2b/3 clinical trial in neovascular (wet) age-related ... Read More

KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data

pharmanewsdaily- July 11, 2020

KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the ... Read More

DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial

pharmanewsdaily- October 15, 2019

Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer ... Read More

Kodiak enrolls patients for retinal disease drug KSI-301’s phase 1 trial

pharmanewsdaily- September 2, 2018

Clinical trial news : Kodiak Sciences has completed enrollment of patients for a phase 1 safety and tolerability study to evaluate its retinal disease drug ... Read More